Drug Trial Radar · NCT06368882
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease(OCEAN PROJECT)
Last checked: Nov 19, 2026Latest source record: Apr 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Jan 1, 2024
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based medical data of an antiviral treatment programme for chronic viral hepatitis B with nonalcoholic fatty liver disease. A total of 1500 patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease are divided into test group (1000 patients receiving PEG-IFNα-based antiviral therapy (combined NAs or Peg-IFNα monotherapy) and control group(500 patients receiving NAs monotherapy) according to their treatment intention. Laboratory and medical data from specified follow-up points are collected, and adverse events and drug combinations are recorded detailly. The primary efficacy indicator is HBsAg clearance at 48 weeks of treatment, and the secondary indicators included: (1) HBsAg clearance at 96 weeks of treatment, (2) Cumulative HBsAg clearance at week 24、120、144、168、192、216 and 240; (3) The improvement of liver function level(ALT, AST, TBIL, etc.), blood lipid (TC, TG, LDL-C, HDL-C, etc.), fasting blood glucose, insulin resistance index (HOMA-IR), controlled attenuation parameter, body mass index , liver stiffness measurement, liver histological fibrosis, FIB-4 index from baseline; (4)Incidence of liver cirrhosis and hepatocellular carcinoma during follow-up. The security assessment includes adverse events, vital signs, and imaging.
Conditions
- Nonalcoholic Fatty Liver Disease
- Chronic Hepatitis b
Interventions
Peg-Interferon αDrug
Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HBsAg clearanceTime frame: 48 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Ningbo No.2 Hospital
Ningbo, China · Recruiting
Ruian People's Hospital
Rui’an, China · Recruiting
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, China · Recruiting
Wenzhou People's Hospital
Wenzhou, China · Recruiting
Yueqing People's Hospital
Yueqing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.